Part 1: Getting to PrEP - Normalizing Sexual Health Conversations
July 29, 2022
July 29, 2023
Case Management, Infectious Disease, Obstetrics & Gynecology, Pharmacy, Primary Care
AIDS/HIV, Sexually Transmitted Diseases
This activity is jointly provided by Postgraduate Institute for Medicine and Rural Medical Education (RME) Collaborative.
In collaboration with the Southeast AIDS Education & Training Center.
Supported by an independent educational grant from Gilead Sciences, Inc.
- Physicians — maximum of 1.0 AMA PRA Category 1 Credit™
- Nurses — 1.0 Contact Hour (0.5 contact hour of pharmacotherapy credit)
- Pharmacists — 1.0 Contact Hour
All other healthcare professionals completing this course will be issued a statement of participation.
This activity is designed specifically for primary care physicians, nurse practitioners, physician assistants, nurses, pharmacists, social workers, and other health professionals who serve patients in rural and underserved communities.
In rural and underserved areas, primary care clinicians are instrumental in identifying individuals at risk for HIV who may benefit from pre-exposure prophylaxis (PrEP). However, clinician discomfort when initiating and navigating conversations about sexual health can be a barrier to care. This activity, which is Part 1 of a four-part series titled Ending the HIV Epidemic: Strategies to Increase PrEP Uptake in Rural and Underserved Communities, will cover best practices for engaging in open and nonjudgmental discussions about sexual health and history. Guidelines for initiating and maintaining patients on PrEP will also be reviewed.
This activity is a recording from a two-part webinar series that took place in March 2022. Please note that any data, information, and guidance presented in the activity are subject to change.
Upon completion of this activity, participants should be better able to:
- Identify patients at risk of acquiring HIV through improved risk assessment strategies and effective patient/clinician communication
- Evaluate current and emerging PrEP formulations based on safety, efficacy, and dosing profiles
- Apply the latest clinical evidence and treatment recommendations to the management of patients on PrEP
Paul E. Sax, MD
Clinical Director, Division of Infectious Diseases
Brigham and Women’s Hospital
Professor of Medicine
Harvard Medical School
Gregory “Grey” Felzien, MD, AAHIVS
Diplomat: Internal Medicine and Infectious Disease
Division of Medical and Clinical Services
Georgia Department of Public Health
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and RME Collaborative. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour. Designated for 0.5 contact hour of pharmacotherapy credit for Advanced Practice Registered Nurses.
Continuing Pharmacy Education
Postgraduate Institute for Medicine designates this continuing education activity for 1.0 contact hour(s) (0.1 CEUs) of the Accreditation Council for Pharmacy Education.
(Universal Activity Number - JA4008162-9999-22-298-H02-P)
Type of Activity: Application
For Pharmacists: Upon successfully completing the post-test with a score of 75% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service.
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine and RME Collaborative adhere to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Postgraduate Institute for Medicine requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies (commercial interests). All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to Postgraduate Institute for Medicine policy. Postgraduate Institute for Medicine is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:
Paul E. Sax, MD, has disclosed the following relevant financial relationships: scientific advisory board member/consultant for Gilead Sciences, Inc., GlaxoSmithKline/ViiV Healthcare, Janssen Pharmaceuticals, and Merck & Co., Inc.; and research support from Gilead Sciences, Inc., GlaxoSmithKline/ViiV Healthcare, and Merck & Co., Inc.
Gregory “Grey” Felzien, MD, AAHIVS, has no relevant financial relationships to disclose.
Planners, Managers, and Reviewer
The Postgraduate Institute for Medicine and RME Collaborative planners, managers, and reviewer have nothing to disclose.
Instructions for Participation and Credit
This activity is offered at no cost to participants. To receive CME/CE credit, participants must:
- Review the CME/CE information, including the learning objectives and disclosure statements.
- Complete the pre-test.
- View the online activity.
- Complete the post-test and evaluation form.
Course Viewing Requirements
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
©RME Collaborative, a division of Talem Health, LLC. All Rights Reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Talem Health, LLC is prohibited.
There is no fee for this educational activity.
For general information or questions about this activity, please contact RME Collaborative at 800-913- 9370 or email@example.com.
For questions regarding the certification of this activity, please contact Postgraduate Institute for Medicine at firstname.lastname@example.org.